
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc. operates in a growing market, with total ADHD medication sales in the U.S. increasing approximately 8% annually since 2010, reaching about $18 billion in 2020, which reflects strong demand for ADHD treatments. The company has reported positive trial data for its lead product candidate, CTx-1301, showing efficacy compared to placebo, which potentially enhances its market position and growth prospects. Additionally, the advancement of Cingulate's proprietary precision timed-release drug delivery platform may further diversify its pipeline and create future revenue opportunities as it explores new therapeutic areas.
Bears say
Cingulate Inc reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which underperformed against both internal estimates and consensus expectations. The company's financial outlook is further jeopardized by substantial risks, including liquidity concerns and potential failures in demonstrating the safety and efficacy of its product candidates during clinical trials. Additionally, the challenges of gaining regulatory approvals, securing reimbursement, and navigating competitive pressures contribute to a fundamentally negative perspective on the sustainability of Cingulate's financial performance.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares